Product Description
therapeutic vaccine for advanced solid tumors (Sourced from: https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex992.htm)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ImmunityBio
Company Location: SAN DIEGO CA 92121
Company CEO: Richard Adcock
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Triple Negative Breast Cancer|Squamous Cell Carcinoma|Melanoma|Head and Neck Cancer|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Carcinoma, Merkel Cell|Transitional Cell Carcinoma|Hepatocellular Carcinoma|Chordoma|Ovarian Cancer|Colorectal Cancer
Phase 1: Prostate Cancer|Breast Cancer|Lung Cancer|Colorectal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03481816 |
18-C-0073 | P1 |
Completed |
Prostate Cancer |
2020-01-15 |
2021-05-20 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT03384316 |
18-C-0032 | P1 |
Completed |
Lung Cancer|Breast Cancer|Colorectal Cancer|Prostate Cancer |
2018-05-22 |
2020-09-16 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT03387085 |
QUILT-3.067 | P2 |
Terminated |
Triple Negative Breast Cancer |
2020-09-11 |
45% |
2024-08-10 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |
NCT03647423 |
QUILT-3.091 | P2 |
Withdrawn |
Chordoma |
2020-08-31 |
50% |
2021-03-16 |
Primary Endpoints|Treatments |
NCT03554109 |
TNBC | P2 |
Withdrawn |
Triple Negative Breast Cancer |
2020-06-01 |
50% |
2024-11-27 |
Primary Endpoints|Treatments |
NCT03563144 |
QUILT-3.088 | P2 |
Withdrawn |
Pancreatic Cancer |
2019-12-30 |
12% |
2021-03-16 |
Primary Endpoints|Treatments |
NCT03563170 |
QUILT-3.072 | P2 |
Withdrawn |
Hepatocellular Carcinoma |
2019-08-23 |
50% |
2021-03-16 |
Primary Endpoints|Treatments |
NCT03387111 |
QUILT-3.090 | P2 |
Terminated |
Squamous Cell Carcinoma |
2019-04-17 |
50% |
2024-08-06 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT03586869 |
QUILT-3.080 | P2 |
Terminated |
Pancreatic Cancer |
2019-04-17 |
50% |
2024-08-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT03197584 |
QUILT-3.051 | P2 |
Withdrawn |
Ovarian Cancer |
2019-02-01 |
2021-03-16 |
||
NCT03169777 |
QUILT-3.050 | P2 |
Withdrawn |
Colorectal Cancer |
2019-01-01 |
2021-03-16 |
Primary Endpoints|Treatments |
|
NCT03169738 |
QUILT-3.044 | P2 |
Withdrawn |
Non-Small-Cell Lung Cancer |
2019-01-01 |
2021-03-16 |
Primary Endpoints|Treatments |
|
NCT03169764 |
QUILT-3.047 | P2 |
Withdrawn |
Squamous Cell Carcinoma|Head and Neck Cancer |
2019-01-01 |
2021-03-16 |
Primary Endpoints|Treatments |
|
NCT03175666 |
QUILT-3.049 | P2 |
Withdrawn |
Triple Negative Breast Cancer |
2019-01-01 |
2021-03-16 |
||
NCT03197571 |
QUILT-3.048 | P2 |
Withdrawn |
Transitional Cell Carcinoma |
2019-01-01 |
2025-08-27 |
Primary Endpoints|Study Completion Date|Treatments |
|
NCT03167164 |
QUILT-3.045 | P2 |
Withdrawn |
Carcinoma, Merkel Cell |
2019-01-01 |
2021-03-16 |
||
NCT03167177 |
QUILT-3.046 | P2 |
Withdrawn |
Melanoma |
2019-01-01 |
2021-03-16 |
Primary Endpoints|Treatments |
|
NCT03574649 |
QUILT-2.024 | P2 |
Withdrawn |
Non-Small-Cell Lung Cancer |
2018-08-01 |
50% |
2025-02-22 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/21/2020 |
News Article |
Prostate Specific Antigen - Pipeline Review, H2 2019 - ResearchAndMarkets.com |